DDInter344 DDInter1340
Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it is responsible for regulating epithelial tissue development and homeostasis. EGFR has been implicated in various types of cancer, as it is often overexpressed in malignant cells and EGFR overexpression has been linked to more advanced disease and poor prognosis. EGFR is often mutated in certain types of cancer and serves as a driver of tumorigenesis. _In vitro_, cetuximab was shown to mediate anti-tumour effects in numerous cancer cell lines and human tumour xenografts. Approved by the FDA in February 2004 under the brand name
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) treats {v} (Disease) kidney cancer
kidney cancer {u} (Disease) is palliated by {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rabeprazole
Rabeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyl aminolevulinate
Methyl aminolevulinate {u} (Compound) causes {v} (Side Effect) Swelling
Swelling {u} (Side Effect) is caused by {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Capecitabine
Capecitabine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) TIPARP
TIPARP {u} (Gene) is upregulated by {v} (Compound) Omeprazole
Cetuximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) treats {v} (Disease) Barrett's esophagus
Barrett's esophagus {u} (Disease) is treated by {v} (Compound) Omeprazole
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) treats kidney cancer (Disease) and kidney cancer (Disease) is palliated by Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate (Compound) causes Swelling (Side Effect) and Swelling (Side Effect) is caused by Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates TIPARP (Gene) and TIPARP (Gene) is upregulated by Omeprazole (Compound)
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) treats Barrett's esophagus (Disease) and Barrett's esophagus (Disease) is treated by Omeprazole (Compound)